BOSTON and LONDON – September 5, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
Press Release
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
Live moderated webcast on Thursday, September 4th at 4:00 PM ET Access the event here BOSTON and LONDON – September 3, 2025 – Akari Therapeutics, Plc …
[Read more...] about Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Live video webcast on Tuesday, August 19th at 2:00 PM ET BOSTON and LONDON – August 14, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology …
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Abizer Gaslightwala, President and CEO of Akari Therapeutics discussed Akari’s commitment to continued research to better understand the multiple effects of its …
[Read more...] about Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of …
